Wecome Pharmaceutical Co Ltd (300878) — Capital Reinvestment Ratio
Wecome Pharmaceutical Co Ltd (300878) has a Capital Reinvestment Ratio of 0.01x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥50.89 Million) in capital expenditures (CN¥389.97K). See 300878 net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Wecome Pharmaceutical Co Ltd Capital Reinvestment Ratio (2013–2023)
This chart tracks Wecome Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 10 annual periods. Check Wecome Pharmaceutical Co Ltd (300878) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Wecome Pharmaceutical Co Ltd (2013–2023)
Year-by-year Capital Reinvestment Ratio for Wecome Pharmaceutical Co Ltd from 2013 to 2023. For live market cap and broader valuation context, see market value of Wecome Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 2.39x | CN¥58.29 Million | CN¥139.29 Million | ▲ +41.0% |
| 2022 | 1.70x | CN¥146.57 Million | CN¥248.44 Million | ▼ -52.4% |
| 2020 | 3.56x | CN¥42.81 Million | CN¥152.34 Million | ▲ +249.0% |
| 2019 | 1.02x | CN¥112.76 Million | CN¥114.98 Million | ▼ -37.7% |
| 2018 | 1.64x | CN¥105.57 Million | CN¥172.73 Million | ▲ +12.9% |
| 2017 | 1.45x | CN¥29.00 Million | CN¥42.04 Million | ▲ +202.7% |
| 2016 | 0.48x | CN¥100.15 Million | CN¥47.97 Million | ▼ -63.1% |
| 2015 | 1.30x | CN¥29.63 Million | CN¥38.48 Million | ▲ +46.9% |
| 2014 | 0.88x | CN¥46.01 Million | CN¥40.68 Million | ▲ +100.2% |
| 2013 | 0.44x | CN¥25.98 Million | CN¥11.48 Million | — |